title: Efficacy of twice-daily amoxycillin/clavulanate in lower respiratory tract infections.
abstract: In this double-blind, double-dummy study, 324 patients with clinical evidence of community-acquired pneumonia (CAP) or an acute exacerbation of chronic bronchitis were randomly assigned to receive 10 days' treatment with either amoxycillin/clavulanate 875/125 mg twice daily or amoxycillin/clavulanate 500/125 mg three times daily. At the end of therapy, clinical success rates were 92.4% for the twice daily regimen and 94.2% for the three times daily regimen. There was no statistically significant difference between treatments (p = 0.647) and the 95% confidence interval around the treatment difference indicated that the two treatments were equivalent. Treatment equivalence was also confirmed at follow-up, four weeks after the end of treatment. Both regimens were well tolerated. In conclusion, amoxycillin/clavulanate 875/125 mg twice daily is as effective as amoxycillin/clavulanate 500/125 mg three times daily for the treatment of community-acquired lower respiratory tract infections and could improve patient compliance.
authors.affiliation: Department of Medicine, Philippine General Hospital, Manila, Philippines.
authors.forename: A A
authors.initials: AA
authors.lastname: Balgos
authors.forename: G
authors.initials: G
authors.lastname: Rodriguez-Gomez
authors.forename: R
authors.initials: R
authors.lastname: Nasnas
authors.forename: A A
authors.initials: AA
authors.lastname: Mahasur
authors.forename: B P
authors.initials: BP
authors.lastname: Margono
authors.forename: J C
authors.initials: JC
authors.lastname: Tinoco-Favila
authors.forename: R H
authors.initials: RH
authors.lastname: Sansores-Martinez
authors.forename: M
authors.initials: M
authors.lastname: Hassan
authors.forename: O
authors.initials: O
authors.lastname: Beppo
authors.forename: A
authors.initials: A
authors.lastname: Wongsa
authors.forename: A
authors.initials: A
authors.lastname: Cukier
authors.forename: F
authors.initials: F
authors.lastname: Vargas
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000008:administration & dosage* / Q000009:adverse effects; D001991:Bronchitis / Q000188:drug therapy*; D002908:Chronic Disease; D017714:Community-Acquired Infections / Q000188:drug therapy; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D019980:Amoxicillin-Potassium Clavulanate Combination